Co-founder of 23andMe, Anne Wojcicki, said the company has halted research into next-gen sequencing (NGS) of clients' genomic data, choosing to focus on its core business. Although she acknowledged the demand for NGS, she also said, “We want to give information to individuals where there's no ambiguity.” The move comes as a number of companies are trying to make sense out of the explosion in data generated by big data.
Co-founder of 23andMe, Anne Wojcicki, said the company has halted research into next-gen sequencing (NGS) of clients' genomic data, choosing to focus on its core business. Although she acknowledged the demand for NGS, she also said, “We want to give information to individuals where there's no ambiguity.” The company has recently had some success in reselling the data its customers produce to biotechs and academic researchers.